SAN

82.53

-0.12%↓

MRK1

112.5

+0.72%↑

SHL.DE

46.36

-1%↓

ARGX

478.4

-0.52%↓

FRE

42.39

+0.86%↑

SAN

82.53

-0.12%↓

MRK1

112.5

+0.72%↑

SHL.DE

46.36

-1%↓

ARGX

478.4

-0.52%↓

FRE

42.39

+0.86%↑

SAN

82.53

-0.12%↓

MRK1

112.5

+0.72%↑

SHL.DE

46.36

-1%↓

ARGX

478.4

-0.52%↓

FRE

42.39

+0.86%↑

SAN

82.53

-0.12%↓

MRK1

112.5

+0.72%↑

SHL.DE

46.36

-1%↓

ARGX

478.4

-0.52%↓

FRE

42.39

+0.86%↑

SAN

82.53

-0.12%↓

MRK1

112.5

+0.72%↑

SHL.DE

46.36

-1%↓

ARGX

478.4

-0.52%↓

FRE

42.39

+0.86%↑

Search

Sartorius AG

Abrir

SetorSaúde

220.8 1.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

216

Máximo

225

Indicadores-chave

By Trading Economics

Rendimento

70M

100M

Vendas

-24M

883M

P/E

Médio do Setor

152.336

50.291

EPS

1.23

Rendimento de Dividendos

0.35

Margem de lucro

11.268

Funcionários

13,573

EBITDA

147M

296M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+19.31% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.35%

2.40%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.3B

13B

Abertura anterior

219.24

Fecho anterior

220.8

Sentimento de Notícias

By Acuity

18%

82%

30 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Sartorius AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de jun. de 2025, 23:49 UTC

Ganhos

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 de jun. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 de jun. de 2025, 21:30 UTC

Ganhos

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 de jun. de 2025, 21:07 UTC

Ganhos

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 de jun. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 de jun. de 2025, 23:39 UTC

Conversa de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 de jun. de 2025, 23:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 de jun. de 2025, 23:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 de jun. de 2025, 23:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 de jun. de 2025, 23:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 de jun. de 2025, 23:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 de jun. de 2025, 23:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 de jun. de 2025, 23:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 de jun. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 de jun. de 2025, 23:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 de jun. de 2025, 22:06 UTC

Ganhos

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 de jun. de 2025, 21:15 UTC

Ganhos

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 de jun. de 2025, 21:07 UTC

Ganhos

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 de jun. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 de jun. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 de jun. de 2025, 21:06 UTC

Conversa de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 de jun. de 2025, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 de jun. de 2025, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 de jun. de 2025, 20:52 UTC

Ganhos

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 de jun. de 2025, 20:51 UTC

Ganhos

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Sartorius AG Previsão

Preço-alvo

By TipRanks

19.31% parte superior

Previsão para 12 meses

Média 255.33 EUR  19.31%

Máximo 310 EUR

Mínimo 217 EUR

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Sartorius AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

4

Comprar

9

Manter

0

Vender

Pontuação Técnica

By Trading Central

227 / 232Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

30 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sartorius AG

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.